Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer
Natalie Pilla is leaving the lab to become a PhD student at Stanford University. Congrats and good luck, Natalie!
DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer
Elizabeth Luo, a Northeastern University undergrad, joins the lab as a summer intern. Welcome Elizabeth!
Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC
ME25: Strategies for developing combinatorial therapies for Ras-driven cancers.
USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities
Patrick and Amy present at Cancer Research UK - National Cancer Institute’s Cancer Grand Challenges Future Leaders Conference in Barcelona, Spain
Karen is an invited speaker at the Mechanisms & Models of Cancer conference at Cold Spring Harbor Laboratory